MediciNova Inc., a biopharmaceutical company listed on NASDAQ and the Tokyo Stock Exchange, provided a corporate update in a letter from CEO Yuichi Iwaki. In 2025, the company completed patient enrollment for three clinical trials and launched a large-scale Expanded Access Program for Amyotrophic Lateral Sclerosis (ALS), supported by a $22 million NIH research grant. As of December 15, 2025, the ALS program had 87 patients enrolled across 12 U.S. sites. For MN-001 (tipelukast), enrollment was completed in November 2025 for the Phase 2 NATG-202 study targeting hypertriglyceridemia, non-alcoholic fatty liver disease (NAFLD), and Type 2 diabetes (T2DM), with top-line data expected in summer 2026. Recent academic collaboration identified a novel mechanism for MN-001 and its metabolite MN-002 in cholesterol and lipid metabolism. Regarding MN-166 (ibudilast), the COMBAT-ALS Phase 2b/3 trial completed enrollment in September 2025, with top-line results anticipated by year-end after the final participant completes the 12-month treatment period. The OXTOX Phase 2b investigator-initiated trial for chemotherapy-induced peripheral neuropathy in metastatic colon cancer also completed enrollment in December 2025, with ongoing treatment and results timing yet to be determined.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MediciNova Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9620412-en) on January 06, 2026, and is solely responsible for the information contained therein.